TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11252212
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (n=49) received meal plans, recipes, and nutritional information during monthly group office sessions
Study: 9416938
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg 2 times daily)
Study: 9416938
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg 2 times daily) + Aspirin (325 mg/day)
Study: 9416938
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg/day) + Aspirin (325 mg/day)
Study: 8295813
Drug: Clarithromycin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 7.5 mg/kg twice daily, maximum 500 mg twice daily (n = 161)
Study: 8295813
Drug: Amoxicillin/clavulanate 13.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate 13.3 mg/kg three times daily, maximum 500 mg three times daily (n = 177)
Study: 3091459
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of Fragmin (anti-FXa: 0.2-0.3 U/ml)
Study: 11443185
Drug: Canrenoate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canrenoate (200 mg as iv bolus at 2000 h, followed by 200 mg infused in 500 mL saline over 4 h up to 2400 h)
Study: 11443185
Drug: Placebo (saline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline, 1.0 mL as iv bolus at 2000 h, followed by 500 mL over 4 h up to 2400 h)
Study: 25258407
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg/day for 14 days
Study: 18793544
Drug: Cockroft and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cockroft and Gault (C&G)
Study: 16041739
Drug: Atrisin (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrisin (three capsules/day)
Study: 2262649
Drug: Intranasal budesonide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal budesonide, 400 micrograms two times a day
Study: 30706457
Drug: 0.05% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% tretinoin cream (TRE) every other night
Study: 30706457
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day oral isotretinoin (ISO)
Study: 30121097
Drug: Talking with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talking with Teens about Traffic Safety Program (treatment group)
Study: 20473056
Drug: 10-mg intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg intramuscular olanzapine
Study: 20473056
Drug: 10-mg orally
Normalized name: rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-mg orally disintegrating olanzapine tablets
Study: 20473056
Drug: 3-mg oral
Normalized name: glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-mg oral risperidone solution
Study: 20473056
Drug: 7.5-mg intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5-mg intramuscular haloperidol
Study: 17852863
Drug: NO-generating solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO-generating solution
Study: 17852863
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution (hydrochloric acid pH 1.0)
Study: 17852863
Drug: Nitrous acid
Normalized name: Nitrous acid
DrugBank: Nitrous acid (DB09112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrous acid solution
Study: 12649048
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dietary advice and exercise
Study: 1479709
Drug: rEPO administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: rEPO administered twice a week (group A)
Study: 1479709
Drug: rEPO administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: rEPO administered once a week (group B)
Study: 6463067
Drug: Midazolam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1 to 0.15 mg/kg) with suxamethonium (1 mg/kg)
Study: 6463067
Drug: Midazolam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1 to 0.15 mg/kg) with pancuronium (0.075 mg/kg)
Study: 30513095
Drug: CEE plus
Normalized name: Ecee Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE plus 2.5 mg/d of medroxyprogesterone acetate (MPA)
Study: 25133471
Drug: Oxandrolone (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (0.03 mg/kg per day or 0.06 mg/kg per day)
Study: 11834851
Drug: Vehicle (steroid-free)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (steroid-free) with wet-wrap dressings
Study: 2525897
Drug: Transdermal clonidine
Normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal clonidine and Placebo
Study: 30677506
Drug: roniciclib plus
Normalized name: Roniciclib
DrugBank: Roniciclib (DB12974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roniciclib plus chemotherapy
Study: 29136094
Drug: Omega-3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation (800 mg docosahexanoic acid and up to 225 mg eicosapentanoic acid)
Study: 26508094
Drug: TMZ/ABT‐888 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMZ/ABT‐888 (40 mg BID ABT‐888 with 75 mg/m² TMZ for 21 days)
Study: 26508094
Drug: TMZ/ABT‐888 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMZ/ABT‐888 (40 mg BID ABT‐888 with 150-200 mg/m² TMZ for 5 days)
Study: 24821941
Drug: XSPI, central
Approvals — FDA: no, EMA: no, PMDA: no
Description: XSPI, central systolic blood pressure, central augmentation pressure, central pulse pressure, integral of reservoir pressure
Study: 24821941
Drug: XSPI, augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: XSPI, augmentation pressure, central pulse pressure
Study: 16287051
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy and routine care
Study: 12058514
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy training
Study: 9865017
Drug: Metopress-retard 100
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metopress-retard 100 mg taken at 8 a.m.
Study: 9865017
Drug: Metopress-retard 100
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metopress-retard 100 mg taken at 8 p.m.
Study: 7783666
Drug: Sorbitol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol (2.5 to 20 g in iso-osmolar solutions)
Study: 7783666
Drug: Sorbitol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol (20 g)
Study: 7783666
Drug: Sorbitol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol (up to 10 g)
Study: 2547300
Drug: Pea fiber
Normalized name: Pea fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pea fiber (PF) 15 g
Study: 2547300
Drug: Control meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control meal (150 g ground beef, 50 g glucose, 20 g lactulose)
Study: 24986094
Drug: Glycopyrronium (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium (400 µg, single inhaled supra-therapeutic dose)
Study: 22818144
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg PD‐0299685 daily
Study: 22818144
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg PD‐0299685 daily
Study: 17334512
Drug: NCX 4016
Normalized name: NCX 701
DrugBank: NCX 701 (DB05409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCX 4016 (800 mg b.i.d.)
Study: 17334512
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg o.d.)
Study: 10030463
Drug: Zatebradine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zatebradine 10 mg i.v. (n = 24)
Study: 23933066
Drug: Strength and
Normalized name: Excedrin Extra Strength and Excedrin Tension Headache KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength and endurance training performed twice a week (SE2, n=12)
Study: 16884320
Drug: Febuxostat 10-240
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 10-240 mg
Study: 10564141
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (NP) infusion (0.3-1.0 microgram.kg(‐1).min(‐1))
Study: 8638581
Drug: Treatment without
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment without extraction
Study: 1666275
Drug: All surgical
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All surgical treatments
Study: 6339312
Drug: Furosemide (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (80 mg/day, increased to 160 mg/day if no response)
Study: 6339312
Drug: Spironolactone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (150 mg/day, increased to 300 mg/day if no response)
Study: 28825423
Drug: DMXB-A 150
Normalized name: DMXB-A
DrugBank: GTS-21 (DB05708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMXB-A 150 mg (extended-release formulation) administered four times daily for 1 month
Study: 23689047
Drug: Oxygen-driven nebulization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen-driven nebulization (ODN) at 4-5 L/min
Study: 23689047
Drug: Oxygen-driven nebulization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen-driven nebulization (ODN) at 6-7 L/min
Study: 23689047
Drug: Oxygen-driven nebulization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen-driven nebulization (ODN) at 8-9 L/min
Study: 21086650
Drug: Glucose-salt solutions
Normalized name: glucose Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-salt solutions
Study: 12848774
Drug: Retigabine 200
Normalized name: retigabine 200 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retigabine 200 mg
Study: 12848774
Drug: Retigabine 200
Normalized name: retigabine 200 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retigabine 200 mg every 8 h on day 32
Study: 12848774
Drug: Phenobarbitone 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone 90 mg
Study: 12848774
Drug: Phenobarbitone 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone 90 mg after retigabine administration
Study: 10493336
Drug: 5-component acellular
Normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-component acellular pertussis vaccine
Study: 8902922
Drug: Vigabatrin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (2 g daily)
Study: 1988239
Drug: Magnesium hydroxide
Normalized name: Magnesium Hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium hydroxide (850 mg) with glipizide (5 mg)
Study: 1988239
Drug: Control (water)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (water) with glipizide (5 mg)
Study: 6294732
Drug: Intramuscular sincalide
Normalized name: Sincalide
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular sincalide
Study: 6294732
Drug: Intravenous sincalide
Normalized name: Sincalide
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous sincalide
Study: 30108163
Drug: Glutamine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (5 g t.i.d.)
Study: 28547078
Drug: 4% articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% articaine with 1:100,000 adrenaline as buccal and lingual infiltration
Study: 23979151
Drug: Various antibiotics
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various antibiotics tested (excluding imipenem)
Study: 19682170
Drug: Isoproterenol (ISO)
Normalized name: isoproterenol sulfate Metered Dose Inhaler [Medihaler-Iso]
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoproterenol (ISO) administered in escalating doses of 5, 10, 15, and 20 microg/min
Study: 18845996
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (DOX) 60 mg/m² every 3 weeks
Study: 18845996
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) 50 mg/m² every 4 weeks
Study: 8455319
Drug: Simultaneous infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous infusion of all substrates with bolus‐based intermittent infusions during 60 minutes six times per day (24 hours)
Study: 8455319
Drug: Sequential infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential infusion of fat plus amino acids at a constant rate over 12 hours during daytime followed by glucose infusion at a constant rate for 12 hours during nighttime
Study: 8455319
Drug: Simultaneous infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous infusion of all substrates at a constant rate over 24 hours
Study: 3510410
Drug: Dexamethasone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (40 mg/m2 for doxorubicin, 95 mg/m2 for cis-platinum) administered intravenously 15 min prior to chemotherapy
Study: 29758154
Drug: Oscillating-rotating electric
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oscillating-rotating electric rechargeable toothbrush (Oral-B® PRO 1000, D16U)
Study: 26058585
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose theophylline (Uniphyllin MR 200 mg tablets)
Study: 18155202
Drug: Pre-ART cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-ART cycle screening with saline infusion sonohysterography
Study: 16580384
Drug: Intranasal E2/NET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal E2/NET (175 microg/275 microg) as a spray
Study: 16580384
Drug: Oral E2/NETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E2/NETA (1 mg/0.5 mg) as a capsule
Study: 9586788
Drug: Oral, semielemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, semielemental diet (SED)
Study: 3041336
Drug: Widely available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Widely available topical preparation
Study: 29843761
Drug: Electro-acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-acupuncture treatment for 10 days in addition to routine pharmacological treatment.
Study: 29843761
Drug: Routine pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine pharmacological treatment alone (Control group).
Study: 26232375
Drug: Romosozumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romosozumab (1 or 2 mg/kg Q2W or 2 or 3 mg/kg Q4W)
Study: 21917894
Drug: Darunavir/ritonavir (DRV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir (DRV/r) monotherapy
Study: 17046383
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia (no additional medication)
Study: 17046383
Drug: Sublingual lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual lorazepam (0.5 to 1 mg, approximately 20 min preoperatively)
Study: 17046383
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedation (fentanyl and midazolam, doses from 50 to 125 microg of fentanyl and 1‐2 mg of midazolam)
Study: 1546818
Drug: Ketotifen (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (0.8 mg for <14 kg, 1.2 mg for ≥14 kg)
Study: 31517555
Drug: Kaempferia parviflora
Normalized name: Kaempferia galanga root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaempferia parviflora extract (KPE) - 5 tablets daily (150 mg KPFORCE™/tablet) for 4 weeks
Study: 31517555
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 5 tablets daily for 4 weeks
Study: 19918712
Drug: 0.5% Boswellic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% Boswellic acid cream
Study: 19918712
Drug: Base cream
Normalized name: U-Base Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Base cream without Boswellic acid
Study: 16000173
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (endoscopy into the sacral level without adhesiolysis, followed by injection of local anesthetic and steroid)
Study: 12140473
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using methyl 5‐aminolevulinate cream 160 mg/g, 3 hours application time, and red light (75 J/cm(2))
Study: 12140473
Drug: Cryotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy with liquid nitrogen spray
Study: 12140473
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using methyl 5‐aminolevulinate
Study: 7675960
Drug: Buprenorphine (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (2, 4, and 8 mg sl.)
Study: 7675960
Drug: Methadone (15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (15, 30, and 60 mg PO)
Study: 25567367
Drug: ABT-639 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-639 (up to 170 mg single dose and up to 160 mg BID multiple doses)
Study: 16933268
Drug: High-dose methyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methyl prednisolone (HDMP)
Study: 11270019
Drug: Remifentanil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (1 microgram kg‐1 bolus followed by 0.1 microgram kg‐1 min‐1 infusion)
Study: 11270019
Drug: Sufentanil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (0.1 microgram kg‐1 bolus over 60 s followed by 0.01 microgram kg‐1 min‐1 infusion)
Study: 3810050
Drug: Pivampicillin/pivmecillinam (PAPM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin/pivmecillinam (PAPM) 450 mg and 900 mg every 12 h until catheter removal (max 1 week)
Study: 3810050
Drug: Cefotaxime (CFT)
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotaxime (CFT) 1 g daily parenterally
Study: 30376893
Drug: TXA dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA dose A (15 mg/kg bolus dose over 20 min, followed by 2 mg/kg/hr infusion over 8 h)
Study: 30376893
Drug: TXA dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA dose B (30 mg/kg bolus dose over 20 min, followed by 4 mg/kg/hr infusion over 8 h)
Study: 30376893
Drug: TXA dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA dose A
Study: 30376893
Drug: TXA dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA dose B
Study: 20520555
Drug: Colloid infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid infusions (HES and human albumin)
Study: 20520555
Drug: Colloids vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloids vs. lactated Ringer's solution
Study: 17431368
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation utilizing intensity modulated external beam radiation therapy or brachytherapy
Study: 7740638
Drug: Stroke unit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stroke unit treatment using Bobath principles
Study: 7740638
Drug: General medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: General medical unit treatment
Study: 2161614
Drug: Diet A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet A: 227 g canned beans daily in a single dose
Study: 2161614
Drug: Diet B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet B: 227 g canned beans daily in a divided dose
Study: 2161614
Drug: Diet C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet C: 182 g canned beans daily in a divided dose
Study: 7217721
Drug: Killed influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed influenza virus vaccine (A/New Jersey/76)
Study: 27979988
Drug: Histamine receptor
Normalized name: Histamine receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine receptor antagonist
Study: 27979988
Drug: Histamine receptor
Normalized name: Histamine receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine receptor blockade
Study: 24162809
Drug: RT +
Normalized name: CVS Yogurt + Fiber Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT + PCV chemotherapy
Study: 21134328
Drug: HPHchol diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPHchol diet (high-protein high-cholesterol); 590 mg cholesterol; 2 eggs per day; duration 12 weeks
Study: 21134328
Drug: HPLchol diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPLchol diet (high-protein low-cholesterol); 213 mg cholesterol; replaced eggs with 100 g of lean animal protein; duration 12 weeks
Study: 19303978
Drug: Control (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.04 g/min glucose)
Study: 19303978
Drug: High (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: High (0.8 g/min glucose)
Study: 19402905
Drug: Loozit group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loozit group weight management program (G)
Study: 19402905
Drug: Loozit group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loozit group weight management program plus additional therapeutic contact (G+ATC)
Study: 16137403
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg, adjusted to 25 mg or 100 mg according to efficacy and toxicity)
Study: 12045491
Drug: TDF 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF 75 mg
Study: 12045491
Drug: TDF 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF 150 mg
Study: 7237926
Drug: [14C]‐glycocholic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: [14C]‐glycocholic acid (bolus injection or constant infusion)